Immunotherapy for Colorectal Cancer Effusion Using OK-432 and IL-2
Author Information
Author(s): Yamaguchi Y, Miyahara E, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Sawamura A, Toge T
Primary Institution: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Hypothesis
The efficacy of locoregional immunotherapy for malignant effusion using OK-432 plus IL-2 is dependent on the induction of CD4+ effector lymphocytes.
Conclusion
Locoregional administration of OK-432 alone or with IL-2 is highly effective for managing malignant effusion from colorectal cancer.
Supporting Evidence
- 82% response rate with OK-432 alone and 100% with OK-432 plus IL-2.
- Overall response rate of 88% for the treatment.
- Median survival of 8 months for patients treated.
Takeaway
Doctors used a special treatment to help patients with fluid buildup from colorectal cancer, and it worked really well for most of them.
Methodology
Patients received locoregional administration of OK-432 and IL-2, and clinical efficacy was assessed through cytological and imaging examinations.
Limitations
The study did not address the effects on distant metastases, and all patients eventually died.
Participant Demographics
{"age":{"median":59,"range":"39-72"},"gender":{"male":7,"female":9},"performance_status":{"0":1,"1":3,"2":9,"3":3},"primary_operation":{"yes":14,"no":2},"histology":{"differentiated":14,"undifferentiated":2},"effusion":{"pleural":3,"ascites":13},"concurrent_metastasis":{"liver":10,"lung":3,"lymph_nodes":12,"bone":2}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website